Human papillomavirus: Gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies

Future Microbiology

Volumn 5, Issue 10, 2010, Pages 1493-1506

  Graham, Sheila V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

antiviral therapy; diagnostics; gene expression; human papillomavirus; RNA processing; transcription; translation

Indexed keywords

ANTIBODY; ANTISENSE OLIGODEOXYNUCLEOTIDE; IDC 13; IDC 16; IDC 78; INDOLE DERIVATIVE; RIBOZYME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG EFFECT; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; PAPILLOMAVIRUS INFECTION; POLYADENYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RNA PROCESSING; RNA SPLICING; RNA STABILITY; RNA TRANSLATION; UTERINE CERVIX CANCER; UTERINE CERVIX TUMOR; VERRUCA VULGARIS; VIRUS DIAGNOSIS; VIRUS GENOME; VIRUS REPLICATION; WART VIRUS;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTEIN BIOSYNTHESIS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; TRANSCRIPTION, GENETIC;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 78449255932     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.107     Document Type: Review

References (107)

1. Zur Hausen H: Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384, 260-265 (2009).
2. De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hauseng H: Classifcation of papillomaviruses. Virology 324, 17-24 (2004).
3. Stanley MA: Human papillomavirus vaccines. Rev. Med. Virol. 16, 139-149 (2006).
4. Doorbar J, Foo C, Coleman N et al.: Characterisation of events during the late stages of HPV16 infection in vivo using high-affnity synthetic Fabs to E4. Virology 238, 40-52 (1997).
5. Graham SV: Late events in the life cycle of human papillomaviruses. In: Papillomavirus Research: from Natural History to Vaccines and Beyond. Campo MS (Ed.). Caister Academic Press, Norfolk, UK 193-212 (2006).
6. Tang S, Tao M, McCoy JP, Zheng Z-M: The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. 80(9), 4249-4263 (2006).
7. Pim D, Massimi P, Banks L: Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 15, 257-264 (1997).
8. Filippova M, Johnson MM, Bautista M et al.: The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J. Virol. 81(8), 4116-4129 (2007).
9. Pim D, Tomaic V, Banks L: The human papillomavirus (HVP) E6* proteins from high-risk mucosal HPVs can direct degradation of cellular proteins in the absence of full length E6 protein. J. Virol. 83(19), 9863-9874 (2009).
10. Stubenrauch F, Hummel M, Iftner T, Laimins LA: The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes. J. Virol. 74(3), 1178-1186 (2000).
11. Alloul N, Sherman L: Transcription-modulatory activities of differentially spliced cDNAs encoding the E2 protein of human papillomavirus type 16. J. Gen. Virol. 80(9), 2461-2470 (2006).
12. Lace MJ, Anson JR, Thomas GS, Turek LP, Haugen TH: The E8E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensible for viral plasmid persistence in keratinocytes. J. Virol . 82(3), 10841-10853 (2008).
13. Ammermann I, Bruckner M, Matthes F, Iftner T, Stubenrauch F: Inhibition of transcription and DNA replication by the papillomavirus E8E2C protein is mediated by interaction with corepressor molecules. J. Virol. 82(11), 5127-5136 (2008).
14. Patterson NA, Smith JL, Ozbun MA: Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J. Virol. 79(11), 6838-6847 (2005).
15. Shafti-Keramat S, Handisurya A, Kriehuberm E, Slupetzky K, Kirnbauer R: Different heparan sulfate proteoglycans serve as cellular receptors for human papillomaviruses. J. Virol. 77(24), 13125-13135 (2003).
16. Evander M, Frazer IH, Payne E et al.: Identifcation of the a6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71(3), 2449-2456 (1997).
17. McMillan NA, Payne E, Frazer IH, Evander M et al.: Expression of the a6 integrin confers papillomavirus binding upon receptor-negative B-cells. Virol. 261(2), 271-279 (1999).
18. Smith JL, Campos SK, Ozbun MA: Human papillomavirus type 31 uses a caveolin 1- and dynamin 2-mediated entry pathway for infection of human keratinocytes. J. Virol. 81(18), 9922-9931 (2007).
19. You J, Croyle JL, Nishimura A, Ozato K, Howley PM: Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes. Cell 117(3), 349-360 (2004).
20. Ozbun MA: Human papillomavirus type 31b infection of human keratinocytes and the onset of early transcription. J. Virol. 76(2), 11291-11300 (2002).
21. Woodman CBJ, Collins SI, Young LS: The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7, 11-22 (2007).
22. Hamid NA, Brown C, Gaston K: The regulation of cell proliferation by the papillomavirus early proteins. Cell. Mol. Life Sci . 66(10) 1700-1717 (2009).
23. Florin L, Sapp C, Streeck RE, Sapp M: Assembly and translocation of papillomavirus capsid proteins. J. Virol. 76(19), 10009-10014 (2002).
24. Wang Q, Griffn HM, Southern S et al.: Functional analysis of the human papillomavirus type 16E1E4 protein provides a mechanism for in vivo and in vitro keratin flament reorganization. J. Virol. 78(2), 821-833 (2004).
25. Bryan J, Brown DR: Association of the human papillomavirus type 11 E1E4 protein with cornifed cell envelopes derived from infected genital epithelium. Virology 277(2) 262-269 (2000).
26. Lehr E, Jarnik M, Brown DR: Human papillomavirus type 11 alters the transcription and expression of loricrin, the major cell envelope protein. Virology 298(2) 240-247 (2002).
27. Middleton K, Peh W, Southern SA et al.: Organisation of the human papillomavirus productive cycle during neoplastic progression provides a basis for the selection of diagnostic markers. J. Virol. 77(19), 10186-10201 (2003).
28. Kozak M: An analysis of vertebrate mRNA sequences: intimations of translational control. J. Cell Biol. 15(4), 887-903 (1991).
29. Smotkin D, Wettstein FO: Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identifcation of the E7 protein. Proc. Natl Acad. Sci. USA 83(13) 4680-4684 (1986).
30. Ozbun MA, Meyers C: Temporal usage of multiple promoters during the life cycle of human papillomavirus type 31b. J. Virol. 72(4), 2715-2722 (1998).
31. Thierry F, Howley PM: Functional analysis of E2-mediated repression of the HPV18 p105 promoter. New Biol. 3(1), 90-100 (1991).
32. Thierry F, Heard JJ, Dartmann K, Yaniv M: Characterisation of a transcriptional promoter of human papillomavirus 18 and modulation of its expression by simian virus 40 and adenovirus early antigens. J. Virol. 61(1) 134-142 (1987).
33. Grassman K, Rapp B, Maschek H, Petry KU, Iftner T: Identifcation of a differentiation-inducible promoter in the E7 open reading frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new cell line containing high copy numbers of episomal HPV-16 DNA. J. Virol. 70(4), 2339-2349 (1996).
34. Chow LT, Nasseri M, Wolinsky SM, Broker TR: Human papillomavirus types 6 and 11 mRNAs from genital condylomata acuminata. J. Virol. 61(8), 2581-2588 (1987).
35. Smotkin D, Prokoph H, Wettstein FO: Oncogenic and nononcogenic human genital papillomaviruses generate the E7 mRNA by different mechanisms. J. Virol. 63(3), 1441-1447 (1989).
36. Stoler MH, Wolinsky SM, Whitbeck A, Broker TR, Chow LT: Differentiation-linked human papillomavirus types 6 and 11 transcription in genital condylomata revealed by in situ hybridisation with message-specifc RNA probes. Virology 172(1), 331-340 (1989).
37. Karlen S, Offord EA, Beard P: Functional promoters in the genome of human papillomavirus type 6b. J. Gen. Virol. 77(1), 11-16 (1996).
38. Zhao W, Chow LT, Broker TR: Transcription activities of human papillomavirus type 11 E6 promoter-proximal elements in raft and submerged culture of foreskin keratinocytes. J. Virol. 71(11), 8832-8840 (1997). (Pubitemid 27446467)
39. DiLorenzo TP, Steinberg BM: Differential regulation of human papillomavirus type 6 and 11 early promoters in cultures cells derived from laryngeal papillomas. J. Virol. 69(11) 6865-6872 (1995).
40. Carson A, Khan SA: Characterisation of transcription factor binding to human papillomavirus type 16 DNA during cellular differentiation. J. Virol. 80(9), 4356-4362 (2006).
41. Thierry F: Transcriptional regulation of the papillomavirus oncogenes by cellular and viral transcription factors in cervical cancer. Virology 384(2), 375-379 (2009).
42. Wool ridge T, Laimins LA: Regulation of human papillomavirus type 31 gene expression during the differentiation-dependent life cycle through histone modifcations and transcription factor binding. Virology 374(2), 371-380 (2008).
43. Goodwin EC, Naeger LK, Breiding DE, Androphy EJ, DiMaio D: Transactivation-competent bovine papillomavirus E2 protein is specifcally required for effcient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines. J. Virol. 72(5), 3925-3934 (1998).
44. Nishimura A, Ono T, Ishimoto A et al.: Mechanisms of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growth inhibition. J. Virol. 74(8), 3752-3760 (2000).
45. Milligan SG, Veerapraditsin T, Ahamat B, Mole S, Graham SV: Analysis of novel human papillomavirus type 16 late mRNAs in differentiated W12 cervical epithelial cells. Virology 360, 172-181 (2007).
46. Del Mar Pena L, Laimins LA: Differentiation-dependent chromatin rearrangement coincides with activation of human papillomavirus type 31 late gene expression. J. Virol. 75(20), 10005-10013 (2001).
47. Bodily JM, Meyers C: Genetic analysis of the human papillomavirus type 31 differentiation-dependent late promoter. J. Virol. 79(6), 3309-3321 (2005).
48. Zheng Z-M, Baker CC: Papillomavirus genome structure, expression, and post-transcriptional regulation. Front. Biosci. 11, 2286-2302 (2006).
49. Glahder JA, Hansen CN, Vinther J, Madsen BS, Norrild B: A promoter within the E 6 ORF of human papillomavirus type 16 contributes to the expression of the E7 oncoprotein from a monocistronic mRNA. J. Gen. Virol. 84(12), 3429-3441 (2003).
50. Hansen CN, Nielsen L, Norrild B: Activities of E7 promoters in the human papillomavirus type 16 genome during cell differentiation. Virus Res. 150(1-2), 34-42 (2010).
51. Ozbun MA, Meyers C: Characterisation of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. J. Virol. 71(7), 5161-5172 (1997).
52. Doorbar J, Parton A, Hartley K et al.: Detection of novel splicing patterns in a HPV-16-containing keratinocyte cell line. Virology 178(1), 254-262 (1990).
53. Stoler MH, Rhodes CR, Whitbeck A et al.: Human papillomavirus type 16 and 18 gene expression in cervical neoplasia. Human Pathol. 23(2), 117-128 (1992).
54. Beyer-Finkler E, Stoler MH, Girardi F, Pfster HJ: Cell differentiation-related gene expression of human papillomavirus 33. Med. Microbiol. Immunol . 179(4), 185-192 (1990).
55. Crum CP, Barber S, Symbula M et al.: Coexpression of the human papillomavirus type 16 E4 and L1 open reading frames in early cervical neoplasia. Virology 178(1) 238-246 (1990).
56. Terhune SS, Milcarek C, Laimins LA: Regulation of human papillomavirus type 31 polyadenylation during the differentiation-dependent life cycle. J. Virol. 73(9), 7185-7192 (1999).
57. Terhune SS, Hubert WG, Thomas JT, Laimins LA: Early polyadenylation signals of human papillomavirus type 31 negatively regulates capsid gene expression. J. Virol. 75(17), 8147-8157 (2001).
58. Rush M, Zhao X, Schwartz S: A splicing enhancer in the E4 coding region of human papillomavirus type 16 is required for early mRNA splicing and polyadenylation as well as inhibition of premature late gene expression. J. Virol. 79(18), 12002-12015 (2005).
59. Öberg D, Fay J, Lambkin H, Schwartz S: A downstream polyadenylation element in human papillomavirus type 16 L2 encodes multiple GGG motifs and interacts with hnRNP H. J. Virol. 79(14), 9254-9269 (2005).
60. Zhao X, Oberg D, Rush M et al.: A 57-nucleotide upstream early polyadenylation element in human papillomavirus type 16 interacts with hFip1, CstF-64, hnRNP C1/C2 and polypyrimidine tract binding protein. J. Virol. 79(7), 4270-4288 (2005).
61. Wang Z, Burge CB: Splicing regulation: from a parts list of regulatory elements to an integrated splicing code. RNA 14(5) 802-813 (2008).
62. Black DL: Mechanisms of alternative pre-messenger RNA splicing. Annu. Rev. Biochem. 72, 291-336 (2003).
63. Long JC, Caceres JF: The SR protein family of splicing factors: master regulators of gene expression. Biochem. J. 417(1), 15-27 (2009).
64. Martinez-Contreras R, Cloutier P, Shkreta L et al.: hnRNP proteins and splicing control. Adv. Exp. Med. Biol. 623, 123-147 (2007).
65. Eperon IC, Makarova OV, Mayeda A et al.: Selection of alternative 5' splice sites: role of U1 snRNP and models for the antagonistic effects of SF2/ASF and hnRNP A1. Mol. Cell. Biol. 20(2), 8303-8318 (2000).
66. Barash Y, Calarco JA, Gao W et al.: Deciphering the splicing code. Nature 465(7294), 53-59 (2010).
67. Berget S: Exon recognition in vertebrate splicing. J. Biol. Chem. 270(6), 2411-2414 (1995).
68. Zhao X, Fay J, Lambkin H, Schwartz S: Identifcation of a 17-nucleotide splicing enhancer in HPV-16 L1 that counteracts the effect of multiple hnRNP A1-binding splicing silencers. Virology 369, 351-363 (2007).
69. Mole S, McFarlane M, Chuen-Im T et al.: RNA splicing factors regulated by HPV16 during cervical tumour progression. J. Pathol. 219, 383-391 (2009).
70. Mole S, Milligan SG, Graham SV: Human papillomavirus type 16 E2 protein transcriptionally activates the promoter of a key cellular splicing factor, SF2/ASF. J. Virol. 83(1), 357-367 (2009).
71. Stubenrauch F, Colbert AME, Laimins LA: Transactivation by the E2 protein of oncogenic human papillomavirus type 31 is not essential for early and late viral functions. J. Virol. 72(10), 8115-8123 (1998).
72. Sokolowski M, Furneaux H, Schwartz S: The inhibitory activity of the AU-rich RNA element in the human papillomavirus type 1 late 3' untranslated region correlates with its affnity for the elav-like HuR protein. J. Virol. 73(2), 1080-1091 (1999).
73. Sokolowski M, Zhao C, Tan W, Schwartz S: AU-rich mRNA instability elements on human papillomavirus type 1 late mRNAs and c-fos mRNAs interact with the same cellular factors. Oncogene 15(19), 2303-2319 (1997).
74. Sokolowski M, Schwartz S: Heterogeneous nuclear ribonucleoprotein C binds exclusively to the functionally important UUUUU-motifs in the human papillomavirus type-1 AU-rich inhibitory element. Virus Res. 73(2), 163-175 (2001).
75. Tan W, Schwartz S: The rev protein of human immunodefciency virus type 1 counteracts the effect of an AU-rich negative element in the human papillomavirus type 1 late 3́ untranslated region. J. Virol. 69(5), 2932-2945 (1995).
76. Zhao C, Tan W, Sokolowski M, Schwartz S: Identifcation of nuclear and cytoplasmic proteins that interact specifcally with an AU-rich, cis-acting inhibitory sequence in the 3' untranslated region of human papillomavirus type 1 late mRNAs. J. Virol. 70(6), 3659-3667 (1996).
77. Cumming SA, McPhillips MG, Veerapraditsin T, Milligan SG, Graham SV: Activity of the human papillomavirus type 16 late negative regulatory element is partly due to four weak consensus 5' splice sites that bind a U1 snRNP-like complex. J. Virol. 77(9), 5167-5177 (2003).
78. Cumming SA, Repellin CE, McPhillips M et al.: The human papillomavirus type 31 late 3́ untranslated region contains a complex bipartite negative regulatory element. J. Virol. 76(12), 5993-6003 (2002).
79. Chuen-Im T, Zhang J, Milligan SG, McPhillips MG, Graham SV: The alternative splicing factor hnRNP A1 is up-regulated during virus-infected epithelial cell differentiation and binds the human papillomavirus type 16 late regulatory element. Virus Res. 131, 189-198 (2008).
80. Cumming SA, Chuen-Im T, Zhang J, Graham SV: The RNA stability regulator HuR regulates L1 protein expression in vivo in differentiating cervical epithelial cells. Virol. 383, 142-149 (2009).
81. Koffa MD, Graham SV, Takagaki Y, Manley JL, Clements JB: The human papillomavirus type 16 negative regulatory element interacts with three proteins that act at different posttranscriptional levels. Proc. Natl Acad. Sci. USA 97(9), 4677-4682 (2000).
82. Dietrich-Goetz W, Kennedy IM, Levins B, Stanley MA, Clements JB: A cellular 65kDa protein recognizes the negative regulatory element of human papillomavirus late mRNA. Proc. Natl Acad. Sci. USA 94(1), 163-168 (1997).
83. Kennedy IM, Haddow JK, Clements JB: A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability. J. Virol. 65(4), 2093-2097 (1991).
84. Brennan CM, Steitz JA: HuR and mRNA stability. Cell. Mol. Life Sci. 58(2), 266-277 (2001).
85. Collier B, Goobar L, Sokolowski M, Schwartz S: Translational inhibition in vitro of human papillomavirus type 16 L2 mRNA mediated through interaction with heterogeneous ribonucleoprotein K and poly (rC)-binding proteins 1 and 2. J. Biol. Chem. 273(35), 22648-22656 (1998).
86. Sokolowski M, Tan W, Jellne M, Schwartz S: mRNA instability elements in the human papillomavirus type 16 L2 coding region. J. Virol. 72(2), 1504-1515 (1998).
87. Wiklund L, Sokolowski M, Carlsson A, Rush M, Schwartz S: Inhibition of translation by UAUUUAU and UAUUUUUAU motifs of the AU-rich RNA instability element in the HPV-1 late 3' untranslated region. J. Biol. Chem. 277(43), 40462-40471 (2002).
88. Newbury SF: Control of mRNA stability in eukaryotes. Biochem. Soc. Trans. 34(1), 30-34 (2006).
89. Zhou J, Lui WJ, Peng SW, Sun XY, Frazer IH: Papillomavirus capsid protein expression levels depends on the match between codon usage and tRNA availability. J. Virol. 73(6), 4972-4982 (1999).
90. Zhao KN, Lui WJ, Frazer IH: Codon usage bias and A+T content variation in human papillomavirus genomes. Virus Res. 98(2), 95-104 (2003).
91. Gu W, Ding J, Wang X et al.: Generalized substitution of isoencoding codons shortens the duration of papillomavirus L1 protein expression in transiently gene-transfected keratinocytes due to cell differentiation. Nucleic Acids Res. 35(14), 4820-4832 (2007).
92. Doorbar J: The papillomavirus life cycle. J. Clin. Virol . 32S, S7-S15 (2005).
93. McPhillips MG, Veerapraditsin T, Cumming SA et al.: SF2/ASF binds the human papillomavirus type 16 late RNA control element and is regulated during epithelial differentiation. J. Virol. 78(19), 10598-10605 (2004).
94. Fay J, Kelehan P, Lambkin H, Schwartz S: Increased expression of cellular RNA-binding proteins in HPV-induced neoplasia and cervical cancer. J. Med. Virol. 81(5), 897-907 (2009).
95. Bailer SM, Haas J: Connecting viral with cellular interactomes. Curr. Opin. Microbiol. 12(4), 453-459 (2009).
96. Schmitt M, Dalstein V, Waterboer T et al.: Diagnosing cervical cancer and high grade precursors by HPV16 transcription patterns. Cancer Res. 70(1), 249-256 (2010).
97. Green KL, Gaston K: Development of a topical protein therapeutic for human papillomavirus and associated cancers. BioDrugs 20(4), 209-218 (2006).
98. Tiemann K, Rossi JJ: RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol. Med. 1, 142-151 (2009).
99. DiPaolo JA, Alvarez-Salas LM: Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opin. Biol. Ther. 4(8), 1251-1264 (2004).
100. Doorbar J, Griffn H: Intrabody strategies for the treatment of human-papillomavirus-associated disease. Expert Opin. Biol. Ther. 7(5), 677-689 (2007).
101. Maitland NJ, Conway S, Wilkinson NS et al.: Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. J. Pathol. 186, 275-280 (1998).
102. Soret J, Bakkour N, Maire S et al.: Selective modifcation of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proc. Natl Acad. Sci. USA 102(24), 8764-8769 (2005).
103. Bakkour N, Lin Y-L, Maire S et al.: Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Path. 3(10), E159 (2007).
104. Keriel A, Mahuteau-Betzer F, Jacquet C et al.: Protection against retrovirus pathogenesis by SR protein inhibitors. PLoS One 4(2), E4533 (2009).
105. Meisner N-C, Hintersteiner M, Mueller K et al.: Identifcation and mechanistic characterization of low-molecular-weight inhibitors for HuR. Nat. Chem. Biol. 3 (8), 508-515 (2007).
106. Jiang M, Rubbi CP, Milner J: Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides 14, 239-248 (2004).
107. Van Pachterbeke C, Bucella D, Rozenberg S et al.: Topical treatment of CIN2+ by cidofovir: results of a Phase II, double-blind, prospective, placebo-controlled study. Gynecol. Oncol. 115(1), 69-74 (2010).